TG Therapeutics Inc. (TGTX)
NASDAQ: TGTX · Pharmaceutical Preparations · New York, NY
Our rating: Neutral
Neutral reaffirmed at $64.26, moderate conviction, November 10, 2026.
Breaks if: The Neutral call turns Positive if TG Therapeutics reports free cash flow above $150M in either of the next two quarterly filings, confirming that net income is converting to real cash and resolving the earnings-quality overhang. It turns Cautious if revenue growth decelerates to below 25% year-over-year in either of the next two quarterly reports, signaling that BRIUMVI's commercial ramp is flattening before the valuation has been grown into.
Key figures
| Market value | $9.6B |
|---|---|
| Revenue, last 12 months | $898M |
| Net income, last 12 months | $106M |
| Free cash flow, last 12 months | $86M |
| Price to earnings | 90.3× |
| Free cash flow yield | 0.9% |
| Dividend yield | 0.0% |
| Operating margin | 21.5% |
| Return on equity | 18.0% |
| Beta to the S&P 500 | 0.77 |
| Volatility, annualized | 53.4% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $260M | 60.7% | $0.35 | $45M |
| June 30, 2026 | $240M | 70.3% | $0.05 | $39M |
| March 31, 2026 | $205M | 69.6% | $0.12 | −$18M |
| December 31, 2025 | $193M | 78.0% | $0.15 | $20M |
| September 30, 2025 | $162M | 92.8% | $2.43 | −$23M |
| June 30, 2025 | $141M | 92.1% | $0.17 | $7M |
| March 31, 2025 | $121M | 90.4% | $0.03 | −$29M |
| December 31, 2024 | $108M | 146.0% | $0.15 | −$26M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.33B: Claude 28%, Gemini 25%, Mistral 25%
- Diluted earnings per share are at least $0.15: Claude 52%, Gemini 60%, Mistral 55%
- Free cash flow for the quarter is at least $0.02B: Claude 58%, Gemini 80%, Mistral 70%
14 ledger entries and 87 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.